title: The role of observational studies in optimizing the clinical management of chronic myeloid leukemia.
abstract: Survival has increased dramatically for patients with chronic phase chronic myeloid leukemia (CP-CML) using BCR-ABL targeted tyrosine kinase inhibitors, such that life expectancy is expected to approximate that of patients without CP-CML. Randomized controlled trials (RCTs) and observational studies provide valuable insights into the management of chronic diseases such as CP-CML. RCTs are undoubtedly the backbone of clinical research, and the 'gold standard' for evaluating the efficacy and safety of new therapies. However, many questions surrounding the optimal management of patients with CML remain unanswered, and it is widely accepted that these questions will be best answered by evaluating the use of available therapies in clinical practice. Observational studies can extend the knowledge base beyond the clinical trial setting and thus capture a more accurate picture of everyday clinical practice, particularly patients' experiences of long-term CML treatment. There is therefore growing interest in and appreciation of the value of observational research. This review article will examine the relative merits of RCTs and observational studies in the setting of CML, highlighting those factors - such as the advancing age of the CML patient population and growing importance of patient-reported outcomes - that mean that observational studies should play an important role in shaping clinical practice. This article also provides an overview of what observational studies have told us thus far about the optimal management of patients with CML, outlines some of the key remaining unanswered clinical questions in CML, and summarizes ongoing observational studies designed to provide answers to these key questions.
authors: Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 489, New York, NY 10065, USA.
authors: Michael J
authors: MJ
authors: Mauro
authors: Bristol-Myers Squibb, Oncology, Global Health Outcomes, Princeton, NJ, USA.
authors: Catherine
authors: C
authors: Davis
authors: Bristol-Myers Squibb, Oncology, Global Health Outcomes, Princeton, NJ, USA.
authors: Teresa
authors: T
authors: Zyczynski
authors: Emory University School of Medicine, Atlanta, GA, USA.
authors: H Jean
authors: HJ
authors: Khoury
keywords: chronic myeloid leukemia; dasatinib; imatinib; nilotinib; observational study
references: Value Health. 2011 Sep-Oct;14(6):862-6
references: 21914507
references: Am J Hematol. 2011 Jun;86(6):471-4
references: 21538468
references: Blood. 2011 Jul 21;118(3):686-92
references: 21536864
references: Hum Reprod. 2004 Jan;19(1):8-13
references: 14688150
references: Ann Intern Med. 2001 Apr 17;134(8):663-94
references: 11304107
references: Blood. 2011 Apr 7;117(14):3733-6
references: 21346253
references: Blood. 2009 May 28;113(22):5401-11
references: 19349618
references: N Engl J Med. 2003 Mar 13;348(11):994-1004
references: 12637609
references: J Clin Oncol. 2011 Oct 10;29(29):3944-5
references: 21900102
references: N Engl J Med. 2010 Jun 17;362(24):2260-70
references: 20525995
references: Blood. 2011 Oct 20;118(16):4353-8
references: 21846902
references: J Clin Oncol. 2010 May 10;28(14):2381-8
references: 20385986
references: BMJ. 2005 Apr 16;330(7496):895-7
references: 15831878
references: Leuk Res. 2010 Nov;34(11):1472-5
references: 20708799
references: Crit Rev Oncol Hematol. 2012 Feb;81(2):123-35
references: 21435899
references: Arch Intern Med. 2002 Aug 12-26;162(15):1682-8
references: 12153370
references: BMJ Open. 2014 Jan 15;4(1):e004266
references: 24435897
references: Clin Ther. 2007;29 Spec No:1284-92
references: 18046928
references: JAMA. 2006 Dec 6;296(21):2563-71
references: 17101639
references: J Clin Oncol. 2011 Jun 20;29(18):2514-20
references: 21576640
references: BMJ. 1998 Oct 31;317(7167):1258
references: 9794885
references: Curr Med Res Opin. 2010 Feb;26(2):307-17
references: 19961284
references: Cancer. 2011 Oct 1;117(19):4343-54
references: 21413002
references: J Clin Oncol. 2008 Jul 10;26(20):3358-63
references: 18519952
references: Circulation. 2009 Jun 16;119(23):3028-35
references: 19528344
references: Ann Hematol. 2012 May;91(5):679-685
references: 22048790
references: Clin Ther. 1997 Mar-Apr;19(2):346-66
references: 9152572
references: Scand J Prim Health Care. 2009;27(3):141-7
references: 19306158
references: Expert Rev Anticancer Ther. 2004 Feb;4(1):85-96
references: 14748660
references: Cancer. 2003 May 1;97(9):2229-35
references: 12712476
references: Am J Med. 2009 Feb;122(2):114-20
references: 19185083
references: Blood. 2010 Nov 11;116(19):3724-34
references: 20664057
references: Am J Clin Nutr. 2008 Aug;88(2):372-83
references: 18689373
references: N Engl J Med. 2010 Jun 17;362(24):2251-9
references: 20525993
references: Leukemia. 2009 Mar;23(3):602-4
references: 18784744
references: CA Cancer J Clin. 2009 Jan-Feb;59(1):56-66
references: 19147869
references: Oncologist. 2011;16(5):663-71
references: 21471276
references: Heart. 2002 Feb;87(2):101-2
references: 11796537
references: Lancet. 2008 Dec 20;372(9656):2152-61
references: 19101391
references: J Natl Cancer Inst. 2011 Apr 6;103(7):553-61
references: 21422402
references: Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):88-93
references: 22154234
references: J Clin Psychopharmacol. 2005 Jun;25(3):271-5
references: 15876909
references: Cancer Epidemiol. 2013 Jun;37(3):247-54
references: 23411044
references: Osteoporos Int. 2000;11(6):533-6
references: 10982170